Literature DB >> 17786367

Loss of heterozygosity on chromosome 10q23 and mutation of the phosphatase and tensin homolog deleted from chromosome 10 tumor suppressor gene in Korean hepatocellular carcinoma patients.

Jei-Jun Bae1, Jin-Woo Rho, Tae-Jin Lee, Sung-Su Yun, Hong-Jin Kim, Joon-Hyuk Choi, Daewon Jeong, Byeong-Churl Jang, Tae-Yoon Lee.   

Abstract

Loss of heterozygosity (LOH) in the 10q23 chromosomal region was analyzed in 18 tissue samples from Korean hepatocellular carcinoma (HCC) patients. LOH at the phosphatase and tensin homolog deleted from chromosome 10 (PTEN) region (D10S215, AFMa086wg9 and D10S541) was found in 8 of the 18 (44.4%) HCCs. LOH (20%) and microsatellite instability (26.7%) were also frequently found at the D10S2177 locus, which is located on the telomere side of the PTEN region. LOH was found in other loci, such as AFM280we1 and D10S2281. The presence of LOH in regions other than the PTEN region on chromosome 10q23 suggested the presence of additional tumor suppressor gene(s). PTEN mutation was found in only a subset of HCCs: A single base insertion at the end of the 5'-end splice signal (AG-GUAAGUU) in intron 5 and a silent mutation in exon 6 (codon 188, CTG-Val to CTA). Our data collectively suggest that the genetic alterations of chromosome 10q23, including the PTEN gene, could be important in hepatocarcinogenesis in the Korean population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17786367

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

1.  A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells.

Authors:  Giuseppa Augello; Roberto Puleio; Maria Rita Emma; Antonella Cusimano; Guido R Loria; James A McCubrey; Giuseppe Montalto; Melchiorre Cervello
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

2.  Expansion of hepatic tumor progenitor cells in Pten-null mice requires liver injury and is reversed by loss of AKT2.

Authors:  Vivian A Galicia; Lina He; Hien Dang; Gary Kanel; Christopher Vendryes; Barbara A French; Ni Zeng; Jennifer-Ann Bayan; Wei Ding; Kasper S Wang; Samuel French; Morris J Birnbaum; C Bart Rountree; Bangyan L Stiles
Journal:  Gastroenterology       Date:  2010-09-15       Impact factor: 22.682

3.  Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice.

Authors:  Suchithra Menon; Jessica L Yecies; Hui H Zhang; Jessica J Howell; Justin Nicholatos; Eylul Harputlugil; Roderick T Bronson; David J Kwiatkowski; Brendan D Manning
Journal:  Sci Signal       Date:  2012-03-27       Impact factor: 8.192

4.  Sequencing the full-length of the phosphatase and tensin homolog (PTEN) gene in hepatocellular carcinoma (HCC) using the 454 GS20 and Illumina GA DNA sequencing platforms.

Authors:  Joel A Rodriguez; Jacfranz J Guiteau; Lynne Nazareth; Jeff G Reid; John A Goss; Richard A Gibbs; Marie-Claude Gingras
Journal:  World J Surg       Date:  2009-04       Impact factor: 3.352

5.  Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma.

Authors:  Wenmin Hou; Jibin Liu; Peizhan Chen; Hui Wang; Bang-Ce Ye; Fulin Qiang
Journal:  Oncol Lett       Date:  2014-06-13       Impact factor: 2.967

6.  Crosstalk of LKB1- and PTEN-regulated signals in liver morphogenesis and tumor development.

Authors:  Chengyou Jia; Vivian Medina; Chenchang Liu; Lina He; Daohai Qian; Tu Taojian; Curtis T Okamoto; Bangyan L Stiles
Journal:  Hepatol Commun       Date:  2017-04-01

7.  LncRNA SNHG14 promotes hepatocellular carcinoma progression via H3K27 acetylation activated PABPC1 by PTEN signaling.

Authors:  Hui Zhang; Hong-Bo Xu; Erxat Kurban; Hong-Wu Luo
Journal:  Cell Death Dis       Date:  2020-08-03       Impact factor: 8.469

8.  Context dependent isoform specific PI3K inhibition confers drug resistance in hepatocellular carcinoma cells.

Authors:  Kubra Narci; Deniz Cansen Kahraman; Altay Koyas; Tulin Ersahin; Nurcan Tuncbag; Rengul Cetin Atalay
Journal:  BMC Cancer       Date:  2022-03-24       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.